The Revision of the General Pharmaceutical Legislation: European Parliament Reports

Real-World Evidence (RWE): The need for a multi-stakeholder approach

Rare Reflections: Impact of the OMP revision on rare disease companies in Europe

MDR/IVDR: Recent changes and their implications for EU medical device companies

Trans-Atlantic Innovation : Building bridges between the EU and US life sciences industry

Rare Disease Day 2023: Improving equitable access and diagnosis for people living with a rare disease

The new EU HTA Procedure: Getting it right to improve patients' access to innovative therapies

2022 Year in Review: Perspectives & Resolutions from the EUCOPE Policy Team

Launch Conditionality: The Impact on Small and Mid-Sized Companies

Advanced Therapy Medicinal Products (ATMPs): How they will be affected by the General Pharmaceutical Legislation

Ensuring a robust European Health Data Space (EHDS): Working to create a fit-for-purpose regulatory framework

Unmet Medical Needs (UMN): Towards a new understanding with a focus on underserved areas

Overcoming Barriers: Improving Access for Rare Disease Patients through Cross-Border Healthcare

Increasing Access to Genomic Testing in Europe: The role of national genomics initiatives in increasing uptake of Advanced Diagnostics

What's next for EU Rare Disease Legislation? Its potential implications for patients and pharma entrepreneurs

The European Pharmaceutical Strategy: A patient-centred and future-proof framework?

Fostering an EU Advanced Diagnostics Ecosystem

A Future-proof HTA System in Europe?

Sounds of Science - Trailer